BioPharmSignal logoBioPharmSignal

Biotech News

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Aziyo Biologics (AZYO)Aziyo Biologics2026-06-25 13:46 ESTEarnings

Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies,

Open original release

Related news

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

AZYOAziyo Biologics2026-06-25 13:46 EST

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Regains Compliance with Nasdaq Listing Requirements

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Aziyo Biologics

Aziyo Biologics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

AZYOAziyo Biologics2026-06-26 09:33 EST

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

AZYOAziyo Biologics2026-06-26 09:33 EST

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

AZYOAziyo Biologics2026-06-26 09:33 EST

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

AZYOAziyo Biologics2026-06-26 09:33 EST

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

AZYOAziyo Biologics2026-06-26 09:33 EST

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States